Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease.

Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R, Raffa F, Garrett A, Duley C, Annis K, Wagnon J, Gaines L, Dalal R, Scoville E, Beaulieu DB, Schwartz D, Horst SN.

Inflamm Bowel Dis. 2019 Oct 31. pii: izz253. doi: 10.1093/ibd/izz253. [Epub ahead of print]

PMID:
31671188
2.

Biallelic inherited SCN8A variants, a rare cause of SCN8A-related developmental and epileptic encephalopathy.

Wengert ER, Tronhjem CE, Wagnon JL, Johannesen KM, Petit H, Krey I, Saga AU, Panchal PS, Strohm SM, Lange J, Kamphausen SB, Rubboli G, Lemke JR, Gardella E, Patel MK, Meisler MH, Møller RS.

Epilepsia. 2019 Nov;60(11):2277-2285. doi: 10.1111/epi.16371. Epub 2019 Oct 17.

PMID:
31625145
3.

The MAP1B Binding Domain of Nav1.6 Is Required for Stable Expression at the Axon Initial Segment.

Solé L, Wagnon JL, Akin EJ, Meisler MH, Tamkun MM.

J Neurosci. 2019 May 29;39(22):4238-4251. doi: 10.1523/JNEUROSCI.2771-18.2019. Epub 2019 Mar 26.

PMID:
30914445
4.

Prominent role of forebrain excitatory neurons in SCN8A encephalopathy.

Bunton-Stasyshyn RKA, Wagnon JL, Wengert ER, Barker BS, Faulkner A, Wagley PK, Bhatia K, Jones JM, Maniaci MR, Parent JM, Goodkin HP, Patel MK, Meisler MH.

Brain. 2019 Feb 1;142(2):362-375. doi: 10.1093/brain/awy324.

PMID:
30601941
5.

The ClinGen Epilepsy Gene Curation Expert Panel-Bridging the divide between clinical domain knowledge and formal gene curation criteria.

Helbig I, Riggs ER, Barry CA, Klein KM, Dyment D, Thaxton C, Sadikovic B, Sands TT, Wagnon JL, Liaquat K, Cilio MR, Mirzaa G, Park K, Axeen E, Butler E, Bardakjian TM, Striano P, Poduri A, Siegert RK, Grant AR, Helbig KL, Mefford HC.

Hum Mutat. 2018 Nov;39(11):1476-1484. doi: 10.1002/humu.23632.

PMID:
30311377
6.

The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy.

Baker EM, Thompson CH, Hawkins NA, Wagnon JL, Wengert ER, Patel MK, George AL Jr, Meisler MH, Kearney JA.

Epilepsia. 2018 Jun;59(6):1166-1176. doi: 10.1111/epi.14196. Epub 2018 May 21.

7.

Partial loss-of-function of sodium channel SCN8A in familial isolated myoclonus.

Wagnon JL, Mencacci NE, Barker BS, Wengert ER, Bhatia KP, Balint B, Carecchio M, Wood NW, Patel MK, Meisler MH.

Hum Mutat. 2018 Jul;39(7):965-969. doi: 10.1002/humu.23547. Epub 2018 May 17.

8.

Loss-of-function variants of SCN8A in intellectual disability without seizures.

Wagnon JL, Barker BS, Ottolini M, Park Y, Volkheimer A, Valdez P, Swinkels MEM, Patel MK, Meisler MH.

Neurol Genet. 2017 Jun 7;3(4):e170. doi: 10.1212/NXG.0000000000000170. eCollection 2017 Aug.

9.

Neuronal hyperexcitability in a mouse model of SCN8A epileptic encephalopathy.

Lopez-Santiago LF, Yuan Y, Wagnon JL, Hull JM, Frasier CR, O'Malley HA, Meisler MH, Isom LL.

Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2383-2388. doi: 10.1073/pnas.1616821114. Epub 2017 Feb 13.

10.

Altered gene expression profile in a mouse model of SCN8A encephalopathy.

Sprissler RS, Wagnon JL, Bunton-Stasyshyn RK, Meisler MH, Hammer MF.

Exp Neurol. 2017 Feb;288:134-141. doi: 10.1016/j.expneurol.2016.11.002. Epub 2016 Nov 9.

11.

Cardiac arrhythmia in a mouse model of sodium channel SCN8A epileptic encephalopathy.

Frasier CR, Wagnon JL, Bao YO, McVeigh LG, Lopez-Santiago LF, Meisler MH, Isom LL.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12838-12843. doi: 10.1073/pnas.1612746113. Epub 2016 Oct 26.

12.

SCN8A-Related Epilepsy with Encephalopathy.

Hammer MF, Wagnon JL, Mefford HC, Meisler MH.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2016 Aug 25.

13.

The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoin.

Barker BS, Ottolini M, Wagnon JL, Hollander RM, Meisler MH, Patel MK.

Epilepsia. 2016 Sep;57(9):1458-66. doi: 10.1111/epi.13461. Epub 2016 Jul 4.

14.

SCN8A encephalopathy: Research progress and prospects.

Meisler MH, Helman G, Hammer MF, Fureman BE, Gaillard WD, Goldin AL, Hirose S, Ishii A, Kroner BL, Lossin C, Mefford HC, Parent JM, Patel M, Schreiber J, Stewart R, Whittemore V, Wilcox K, Wagnon JL, Pearl PL, Vanderver A, Scheffer IE.

Epilepsia. 2016 Jul;57(7):1027-35. doi: 10.1111/epi.13422. Epub 2016 Jun 8.

15.

Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy.

Wagnon JL, Barker BS, Hounshell JA, Haaxma CA, Shealy A, Moss T, Parikh S, Messer RD, Patel MK, Meisler MH.

Ann Clin Transl Neurol. 2015 Dec 21;3(2):114-23. doi: 10.1002/acn3.276. eCollection 2016 Feb.

16.

Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy.

Wagnon JL, Meisler MH.

Front Neurol. 2015 May 15;6:104. doi: 10.3389/fneur.2015.00104. eCollection 2015. Review.

17.

Use of Endoscopic Ultrasound to Guide Adalimumab Treatment in Perianal Crohn's Disease Results in Faster Fistula Healing.

Wiese DM, Beaulieu D, Slaughter JC, Horst S, Wagnon J, Duley C, Annis K, Nohl A, Herline A, Muldoon R, Geiger T, Wise PE, Schwartz DA.

Inflamm Bowel Dis. 2015 Jul;21(7):1594-9. doi: 10.1097/MIB.0000000000000409.

PMID:
25985245
18.

Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease.

Horst S, Chao A, Rosen M, Nohl A, Duley C, Wagnon JH, Beaulieu DB, Taylor W, Gaines L, Schwartz DA.

Dig Dis Sci. 2015 Feb;60(2):465-70. doi: 10.1007/s10620-014-3375-0. Epub 2014 Oct 2.

PMID:
25274158
19.

Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy.

Wagnon JL, Korn MJ, Parent R, Tarpey TA, Jones JM, Hammer MF, Murphy GG, Parent JM, Meisler MH.

Hum Mol Genet. 2015 Jan 15;24(2):506-15. doi: 10.1093/hmg/ddu470. Epub 2014 Sep 16.

20.

Rapid, efficient and precise allele replacement in the fission yeast Schizosaccharomyces pombe.

Gao J, Kan F, Wagnon JL, Storey AJ, Protacio RU, Davidson MK, Wahls WP.

Curr Genet. 2014 May;60(2):109-19. doi: 10.1007/s00294-013-0406-x. Epub 2013 Sep 12.

21.

A stress-activated, p38 mitogen-activated protein kinase-ATF/CREB pathway regulates posttranscriptional, sequence-dependent decay of target RNAs.

Gao J, Wagnon JL, Protacio RM, Glazko GV, Beggs M, Raj V, Davidson MK, Wahls WP.

Mol Cell Biol. 2013 Aug;33(15):3026-35. doi: 10.1128/MCB.00349-13. Epub 2013 Jun 3.

22.

CELF4 regulates translation and local abundance of a vast set of mRNAs, including genes associated with regulation of synaptic function.

Wagnon JL, Briese M, Sun W, Mahaffey CL, Curk T, Rot G, Ule J, Frankel WN.

PLoS Genet. 2012;8(11):e1003067. doi: 10.1371/journal.pgen.1003067. Epub 2012 Nov 29.

23.

Aberrant sodium channel activity in the complex seizure disorder of Celf4 mutant mice.

Sun W, Wagnon JL, Mahaffey CL, Briese M, Ule J, Frankel WN.

J Physiol. 2013 Jan 1;591(1):241-55. doi: 10.1113/jphysiol.2012.240168. Epub 2012 Oct 22.

24.

Long-term evaluation of respiratory status after esophageal atresia repair.

Beucher J, Wagnon J, Daniel V, Habonimana E, Fremond B, Lapostolle C, Guillot S, Azzis O, Dabadie A, Deneuville E.

Pediatr Pulmonol. 2013 Feb;48(2):188-94. doi: 10.1002/ppul.22582. Epub 2012 May 22.

PMID:
22619166
25.

Etiology of a genetically complex seizure disorder in Celf4 mutant mice.

Wagnon JL, Mahaffey CL, Sun W, Yang Y, Chao HT, Frankel WN.

Genes Brain Behav. 2011 Oct;10(7):765-77. doi: 10.1111/j.1601-183X.2011.00717.x. Epub 2011 Aug 3.

26.

Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009.

Héritier S, Le Merrer M, Jaubert F, Bigorre M, Gillibert-Yvert M, de Courtivron B, Ziade M, Bertrand Y, Carrie C, Chastagner P, Bost-Bru C, Léonard JC, Ouache M, Boccon-Gibod L, Mary P, de Blic J, Pin I, Wendling D, Revillon Y, Houdoin V, Forin V, Lepointe HD, Languepin J, Wagnon J, Epaud R, Fauroux B, Donadieu J.

Orphanet J Rare Dis. 2010 Feb 3;5:3. doi: 10.1186/1750-1172-5-3.

27.
28.

Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.

Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, Ventura MA.

Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R938-49. Epub 2007 May 23.

29.

[Breastfeeding and vegan diet].

Wagnon J, Cagnard B, Bridoux-Henno L, Tourtelier Y, Grall JY, Dabadie A.

J Gynecol Obstet Biol Reprod (Paris). 2005 Oct;34(6):610-2. French.

30.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A.

CNS Drug Rev. 2005 Spring;11(1):53-68. Review.

31.

Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.

Derick S, Pena A, Durroux T, Wagnon J, Serradeil-Le Gal C, Hibert M, Rognan D, Guillon G.

Mol Endocrinol. 2004 Nov;18(11):2777-89. Epub 2004 Jul 29.

PMID:
15284336
32.

The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.

Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.

J Neuroendocrinol. 2004 Apr;16(4):356-61. Review.

PMID:
15089974
33.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
34.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. Epub 2002 Apr 16.

35.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
36.

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al.

J Clin Invest. 1993 Jul;92(1):224-31.

37.
38.

Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca.

Lacour C, Cazaubon C, Roccon A, Segondy D, Wagnon J, Nisato D.

J Hypertens Suppl. 1989 Apr;7(2):S33-5.

PMID:
2666612
39.

Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.

Nisato D, Wagnon J, Callet G, Mettefeu D, Assens JL, Plouzane C, Tonnerre B, Pliska V, Fauchère JL.

J Med Chem. 1987 Dec;30(12):2287-91.

PMID:
3316655
40.

Conformational preferences and self-association modes of two diastereomeric statine derivatives.

Toniolo C, Valle G, Bonora GM, Lelj F, Barone V, Fraternali F, Callet G, Wagnon J, Nisato D.

Int J Pept Protein Res. 1987 Nov;30(5):583-95.

PMID:
3436695
41.

Conformational analysis of pepstatin and related renin inhibitors by 400 MHz 1H n.m.r. spectroscopy.

Roy P, Delepierre M, Wagnon J, Nisato D, Roques BP.

Int J Pept Protein Res. 1987 Jul;30(1):44-53.

PMID:
3312053
42.

[Personal experience with intermediate prostheses. Apropos of 276 cases].

Lecestre P, Chouteau Y, Bedoucha JS, Fauvy A, Raguin J, Poilbout P, Wagnon J.

Acta Orthop Belg. 1985 Sep-Oct;51(5):790-804. French. No abstract available.

PMID:
4082964
43.

[Leg fractures: choice of treatment according to type of fracture].

Persoons D, Wagnon J, Copin G.

Acta Chir Belg. 1985 Jul-Aug;85(4):274-8. French.

PMID:
4050260
44.

[Colonothoracic fistulas: presentation of 2 cases].

Roy G, Wagnon J, Echavé V, Strom B.

Acta Chir Belg. 1985 May-Jun;85(3):179-83. French.

PMID:
4036460
45.

[Management of fractures of the base of the first metacarpal bone using an external mini-brace. Apropos of a preliminary series of 14 cases].

Nonnenmacher J, Wagnon J, Mochel D, Issa JB.

Acta Orthop Belg. 1981 May-Jun;47(3):399-405. French. No abstract available.

PMID:
7315241
46.

[Place of primary nerve repair using epiperineural sutures. Apropos of 22 cases of median nerve injuries].

Wagnon J, Nonnenmacher J.

Acta Orthop Belg. 1981 May-Jun;47(3):367-74. French. No abstract available.

PMID:
7032188
47.

[Treatment of fractures of the wrist by dynamic fixation].

Nonnenmacher J, Wagnon J, Bouayed C, Kempf I.

Acta Orthop Belg. 1981;47(6):877-83. French. No abstract available.

PMID:
7342667
48.

[Our current concept of the treatment of wrist fractures by compression-extension in the adult].

Nonnenmacher J, Wagnon J, Kempf I.

Acta Orthop Belg. 1981;47(6):870-6. French. No abstract available.

PMID:
7342666
49.

SOME ASPECTS OF CONCERTED REACTIONS IN ORGANOMETALLIC SYSTEMS.

Pettit R, McKennis JS, Slegeir W, Starnes WH Jr, Devon T, Case R, Wagnon JC, Brener L And, Wristers J.

Ann N Y Acad Sci. 1974 Nov;239(1):22-31. doi: 10.1111/j.1749-6632.1974.tb25312.x. No abstract available.

PMID:
28976012
50.

[Stereochemistry. XXXV. Fluorinated steroids. VI. Skeletal rearrangement of 5-androstene 3-beta, 17-beta diol].

Jacquesy JC, Levisalles J, Wagnon J.

Bull Soc Chim Fr. 1970 Feb;2:670-8. French. No abstract available.

PMID:
5418425

Supplemental Content

Loading ...
Support Center